Wade Financial Advisory Inc cut its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 5.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 2,086 shares of the company’s stock after selling 127 shares during the quarter. Wade Financial Advisory Inc’s holdings in Johnson & Johnson were worth $345,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Nwam LLC boosted its stake in shares of Johnson & Johnson by 25.7% in the second quarter. Nwam LLC now owns 33,807 shares of the company’s stock valued at $5,596,000 after purchasing an additional 6,916 shares during the period. Checchi Capital Advisers LLC boosted its stake in Johnson & Johnson by 4.5% during the 2nd quarter. Checchi Capital Advisers LLC now owns 35,054 shares of the company’s stock valued at $5,802,000 after acquiring an additional 1,509 shares during the last quarter. Cetera Advisors LLC boosted its stake in Johnson & Johnson by 2.5% during the 2nd quarter. Cetera Advisors LLC now owns 149,625 shares of the company’s stock valued at $24,766,000 after acquiring an additional 3,682 shares during the last quarter. Meitav Investment House Ltd. boosted its stake in Johnson & Johnson by 2.6% during the 2nd quarter. Meitav Investment House Ltd. now owns 8,361 shares of the company’s stock valued at $1,369,000 after acquiring an additional 210 shares during the last quarter. Finally, King Wealth boosted its stake in Johnson & Johnson by 1.6% during the 2nd quarter. King Wealth now owns 53,043 shares of the company’s stock valued at $8,780,000 after acquiring an additional 848 shares during the last quarter. 68.40% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Upgrades and Downgrades
JNJ has been the topic of a number of research analyst reports. TheStreet downgraded shares of Johnson & Johnson from a “b” rating to a “c+” rating in a research note on Friday. Atlantic Securities raised their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a research report on Friday, August 4th. Raymond James reduced their price target on shares of Johnson & Johnson from $179.00 to $172.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 18th. Wells Fargo & Company reduced their price target on shares of Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating on the stock in a research report on Thursday, August 31st. Finally, Barclays raised their price target on shares of Johnson & Johnson from $158.00 to $162.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 12th. Eight equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $169.19.
Johnson & Johnson Price Performance
Shares of NYSE:JNJ opened at $149.91 on Tuesday. Johnson & Johnson has a one year low of $144.95 and a one year high of $181.04. The stock has a fifty day moving average of $154.52 and a 200-day moving average of $160.29. The company has a market capitalization of $360.88 billion, a PE ratio of 11.13, a price-to-earnings-growth ratio of 3.00 and a beta of 0.58. The company has a debt-to-equity ratio of 0.37, a quick ratio of 0.96 and a current ratio of 1.21.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $2.52 by $0.14. Johnson & Johnson had a return on equity of 37.14% and a net margin of 36.32%. The company had revenue of $21.35 billion during the quarter, compared to the consensus estimate of $21 billion. As a group, equities analysts anticipate that Johnson & Johnson will post 10.1 EPS for the current fiscal year.
Johnson & Johnson Announces Dividend
The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 5th. Investors of record on Tuesday, November 21st will be issued a $1.19 dividend. This represents a $4.76 dividend on an annualized basis and a yield of 3.18%. The ex-dividend date of this dividend is Monday, November 20th. Johnson & Johnson’s dividend payout ratio is presently 35.34%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.
- Five stocks we like better than Johnson & Johnson
- How to Invest in Communication Stocks
- Safeguard your portfolio with these three bargain stocks
- 10 Best Airline Stocks to Buy
- Membership clubs gain leverage for the consumer rebound
- How to Calculate Inflation Rate
- Advanced Auto Parts may be worth more in pieces than the whole
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.